论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)中肺腺癌差异表达基因(DAL-1)单核苷酸多态性(SNP)+1810T/C(rs8082898)与蛋白表达的关系及其对肿瘤发生发展的影响。方法:收集204例NSCLC石蜡组织及其配对正常淋巴结组织,以及112例NSCLC新鲜血液标本,采用PCR-RFLP检测DAL-1基因+1810T/C位点基因型;其中167例NSCLC及其配对癌旁组织SP法检测DAL-1蛋白表达;分析+1810T/C基因型与DAL-1蛋白表达及临床病理特征的关系。结果:在NSCLC中,TT组+1810T/C等位基因频率为92.72%(293/316),CT组为6.33%(20/316),CC组为0.95%(3/316),多态CT+CC组为7.28%(23/316);DAL-1蛋白表达阳性率TT组(59.74%,92/154)与CT+CC组(38.46%,5/13)差异无统计学意义,χ2=0.000,P>0.05。+1810T/C多态在Ⅲ、Ⅳ期高于Ⅰ、Ⅱ期,χ2=11.003,P<0.05;淋巴结转移组高于无转移组,χ2=4.548,P<0.05。NSCLC组DAL-1蛋白表达阳性率(58.08%,97/167)低于对照组(90.42%,151/167),χ2=45.665,P<0.05;高中分化组(63.44%,59/93)高于低分化组(47.30%,35/74),χ2=4.365,P<0.05;Ⅰ期(72.31%,47/65)、Ⅱ期(54.29%,19/35)高于Ⅲ、Ⅳ期合组(46.27%,31/67),χ2=9.450,P<0.05;淋巴结转移组(37.08%,33/89)低于无转移组(82.05%,64/78),χ2=34.532,P<0.05。结论:DAL-1基因+1810T/C位点多态和蛋白表达降低可能在NSCLC的生长及淋巴结转移中发挥作用。
Objective: To investigate the relationship between the expression of single nucleotide polymorphism (SNP) + 1810T / C (rs8082898) and the expression of DAL-1 in non-small cell lung cancer (NSCLC) Impact. METHODS: Totally 204 NSCLC paraffin tissues and matched normal lymph nodes tissues were collected, and 112 fresh blood samples of NSCLC were collected. Genotypes of DAL-1 + 1810T / C loci were detected by PCR-RFLP. The expression of DAL-1 protein was detected by SP method. The relationship between + 1810T / C genotype, DAL-1 protein expression and clinicopathological features was analyzed. Results: In NSCLC, the frequency of 1810T / C allele was 92.72% (293/316) in TT group, 6.33% (20/316) in CT group, 0.95% (3/316) in CC group, The positive rates of DAL-1 protein expression in TT group (59.74%, 92/154) and CT + CC group (38.46%, 5/13) were not statistically different (χ2 = 0.000, P> 0.05. + 1810T / C polymorphism in stage Ⅲ, Ⅳ was higher than stage Ⅰ, Ⅱ, χ2 = 11.003, P <0.05; lymph node metastasis was higher than without metastasis, χ2 = 4.548, P <0.05. The positive rates of DAL-1 protein in NSCLC group (58.08%, 97/167) were lower than those in control group (90.42%, 151/167), χ2 = 45.665, P <0.05; In poorly differentiated group (47.30%, 35/74), χ2 = 4.365, P <0.05; stage Ⅰ (72.31%, 47/65), stage Ⅱ (54.29%, 19/35) (46.27%, 31/67), χ2 = 9.450, P <0.05; The lymph node metastasis group (37.08%, 33/89) was lower than the non-metastasis group (82.05%, 64/78), χ2 = 34.532, P <0.05. CONCLUSION: The decrease of polymorphism and protein expression at + 1810T / C site of DAL-1 gene may play a role in the growth and lymph node metastasis of NSCLC.